Advertisement

Amyloid PET Imaging: Standardization and Integration with Other Alzheimer’s Disease Biomarkers

  • Silvia Morbelli
  • Matteo Bauckneht
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1750)

Abstract

Amyloid plaques are a neuropathologic hallmark of Alzheimer’s disease (AD), which can be imaged through positron emission tomography (PET) technology using radiopharmaceuticals that selectively bind to the fibrillar aggregates of amyloid-β plaques (Amy-PET). Several radiotracers for amyloid PET have been investigated, including 11C-Pittsburgh compound B and the 18F-labeled compounds such as 18F-florbetaben, 18F-florbetapir, and 18F-flutemetamol. Besides the injected radiotracer, images can be interpreted by means of visual/qualitative, semiquantitative, and quantitative criteria. Here we summarize the main differences between the available radiotracers for Amy-PET, the proposed interpretation criteria, and analytical methods.

Key words

Amyloid PET Biomarkers Alzheimer’s disease Brain 

References

  1. 1.
    Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement 7:270–279CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13:614–629CrossRefPubMedGoogle Scholar
  3. 3.
    Teipel S, Drzezga A, Grothe MJ et al (2015) Multimodal imaging in Alzheimer’s disease: validity and usefulness for early detection. Lancet Neurol 14:1037–1353CrossRefPubMedGoogle Scholar
  4. 4.
    Klunk WE, Koeppe RA, Price JC et al (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11:11–15CrossRefGoogle Scholar
  5. 5.
    Guerra UP, Nobili FM, Padovani A et al (2015) Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. Neurol Sci 36:1075–1081CrossRefPubMedGoogle Scholar
  6. 6.
    Minoshima S, Drzezga AE, Barthel H et al (2016) SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med 57:1316–1322CrossRefPubMedGoogle Scholar
  7. 7.
    Garibotto V, Morbelli S, Pagani M (2016) Erratum to: dual-phase amyloid PET: hitting two birds with one stone. Eur J Nucl Med Mol Imaging 43:1747CrossRefPubMedGoogle Scholar
  8. 8.
    Magistretti PJ (2000) Cellular bases of functional brain imaging: insights from neuron-glia metabolic coupling. Brain Res 886:108–112CrossRefPubMedGoogle Scholar
  9. 9.
    Ni R, Gillberg PG, Bergfors A et al (2013) Amyloid tracers detect multiple binding sites in Alzheimer’s disease brain tissue. Brain 136:2217–2227CrossRefPubMedGoogle Scholar
  10. 10.
    Hsiao IT, Huang CC, Hsieh CJ et al (2012) Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging 39:613–620CrossRefPubMedGoogle Scholar
  11. 11.
    Koole M, Lewis DM, Buckley C et al (2009) Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 50:818–822CrossRefPubMedGoogle Scholar
  12. 12.
    O’Keefe GJ, Saunder TH, Ng S et al (2009) Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med 50:309–315CrossRefPubMedGoogle Scholar
  13. 13.
    Chincarini A, Sensi F, Rei L et al (2016) Alzheimer’s Disease Neuroimaging Initiative. Standardized uptake value ratio-independent evaluation of brain amyloidosis. J Alzheimers Dis 54:1437–1457CrossRefPubMedGoogle Scholar
  14. 14.
    Kinahan PE, Fletcher JW (2010) Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 31:496–505CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Clark CM, Pontecorvo MJ, Beach TG et al (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 11:669–678CrossRefPubMedGoogle Scholar
  16. 16.
    Landau SM, Thomas BA, Thurfjell L et al (2014) Alzheimer’s Disease Neuroimaging Initiative. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 41:1398–1407CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    van Berckel BN, Ossenkoppele R, Tolboom N et al (2013) Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med 54:1570–1576CrossRefPubMedGoogle Scholar
  18. 18.
    Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746CrossRefPubMedGoogle Scholar
  19. 19.
    Johnson KA, Minoshima S, Bohnen NI et al (2013) Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement 9:e-1–e-16CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  1. 1.Nuclear Medicine Unit, Polyclinic San Martino HospitalGenovaItaly
  2. 2.Department of Health SciencesUniversity of GenoaGenoaItaly

Personalised recommendations